Category - Developments

Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...

June 13, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

OneMedNet (NASDAQ:ONMD) announced that it has joined the Amazon Web Services (AWS) Partner Network (APN), significantly expanding industry access to its proprietary iRWD platform and securing an undisclosed...

June 6, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Developments

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health...

June 3, 2024

Developments

Verve Therapeutics appoints Troy Lister as CSO

Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity. Currently, Dr. Lister serves as...

June 3, 2024

Developments

OneMedNet inks MSA with top-10 global medtech company

OneMedNet (NASDAQ:ONMD) has entered into a non-exclusive three-year MSA with an undisclosed U.S.-based medical technology company that affects more than 150 million patients worldwide annually. OneMedNet will utilize...

May 30, 2024

Developments

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

Closely-held Lucy Therapeutics (LucyTX) raised $12.5 million in additional funding to further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target...

May 29, 2024

Category - Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Verve Therapeutics appoints Troy Lister as CSO

OneMedNet inks MSA with top-10 global medtech company

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

General

More